Pipeline expansion includes new EGFR and menin inhibitors, with late-stage programs advancing in leukemia, GVHD, and IPF. Multiple clinical milestones are expected through 2027, supported by strong partnerships and a robust financial position.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.